The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine

被引:29
作者
Bousquet, J
Bindslev-Jensen, C
Canonica, GW
Fokkens, W
Kim, H
Kowalski, M
Magnan, A
Mullol, J
van Cauwenberge, P
机构
[1] CHU Montpellier, Hop Arnaud Villeneuve, Dept Resp Dis, Montpellier, France
[2] Odense Univ Hosp, Dept Dermatol, Allergy Ctr, DK-5000 Odense, Denmark
[3] Univ Genoa, Dept Internal Med, Allergy & Resp Dis Clin, I-16126 Genoa, Italy
[4] Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, NL-1105 AZ Amsterdam, Netherlands
[5] McMaster Univ, Fac Hlth Sci, Dept Med, Hamilton, ON L8N 3Z5, Canada
[6] Med Univ Lodz, Fac Med, Dept Allergy & Clin Immunol, Lodz, Poland
[7] Hop St Marguerite, Pneumoallergol Serv, Marseille, France
[8] Hosp Clin Barcelona, ENT Dept, Rhinol Unit, Barcelona, Spain
[9] Univ Ghent, Univ Hosp, Dept Otorhinolaryngol, B-9000 Ghent, Belgium
关键词
antihistamine; allergy; ARIA; desloratadine; guidelines; rhinitis; therapy;
D O I
10.1111/j.1398-9995.2004.00577.x
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: The definition of allergic rhinitis and the classification of its severity and treatment have advanced in recent years following the publication of the Allergic Rhinitis and its Impact of Asthma (ARIA) document. The ARIA and the European Academy of Allergology and Clinical Immunology (ARIA/EAACI) have published a set of recommendations that outline the pharmacological and clinical criteria to be met by medications commonly used in the treatment Of allergic rhinitis. Methods: An international group of experts met to assess the profile of the under the ARIA/EAACI criteria. Data on desloratadine antihistamine, desloratadine were collected from peer-reviewed clinical studies and review articles, which were corroborated and augmented by comprehensive public access documents from the European Medicines Evaluation Agency (EMEA). Results and conclusion: Based on this systematic review, it was concluded that the safety and pharmacology of desloratadine broadly meet the ARIA/efficacy, EAACI criteria for antihistamines.
引用
收藏
页码:4 / 16
页数:13
相关论文
共 45 条
[1]  
*AERIUS, EUR PUBL ASS REP PRO
[2]   A pharmacokinetic profile of desloratadine in healthy adults, including elderly [J].
Affrime, M ;
Gupta, S ;
Banfield, C ;
Cohen, A .
CLINICAL PHARMACOKINETICS, 2002, 41 (Suppl 1) :13-19
[3]   Biochemical characterization of desloratadine, a potent antagonist of the human histamine H1 receptor [J].
Anthes, JC ;
Gilchrest, H ;
Richard, C ;
Eckel, S ;
Hesk, D ;
West, RE ;
Williams, SM ;
Greenfeder, S ;
Billah, M ;
Kreutner, W ;
Egan, RW .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 449 (03) :229-237
[4]  
Assanasen Paraya, 2002, Clin Allergy Immunol, V17, P101
[5]   Desloratadine in the treatment of seasonal allergic rhinitis - Results of a large observational study [J].
Bachert, C ;
Virchow, CJ ;
Plenker, A .
CLINICAL DRUG INVESTIGATION, 2002, 22 (Suppl 2) :43-52
[6]   Comparative effects of desloratadine versus montelukast on asthma symptoms and use of β2-agonists in patients with seasonal allergic rhinitis and asthma [J].
Baena-Cagnani, CE ;
Berger, WE ;
DuBuske, LM ;
Gurné, SE ;
Stryszak, P ;
Lorber, R ;
Danzig, M .
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2003, 130 (04) :307-313
[7]   Constitutive activity of the histamine H1 receptor reveals inverse agonism of histamine H1 receptor antagonists [J].
Bakker, RA ;
Wieland, K ;
Timmerman, H ;
Leurs, R .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 387 (01) :R5-R7
[8]   Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine [J].
Banfield, C ;
Gupta, S ;
Marino, M ;
Lim, J ;
Affrime, M .
CLINICAL PHARMACOKINETICS, 2002, 41 (04) :311-318
[9]   Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole [J].
Banfield, C ;
Herron, J ;
Keung, A ;
Padhi, D ;
Affrime, M .
CLINICAL PHARMACOKINETICS, 2002, 41 (Suppl 1) :37-44
[10]   Lack of clinically relevant interaction between desloratadine and erythromycin [J].
Banfield, C ;
Hunt, T ;
Reyderman, L ;
Statkevich, P ;
Padhi, D ;
Affrime, M .
CLINICAL PHARMACOKINETICS, 2002, 41 (Suppl 1) :29-35